Table 1.

Characteristics of participants at cohort entry overall and stratified by the presence or absence of an episode of AKI during follow-up

Characteristics of participantsTotal, n=2048AKI during Follow-Up, n=324Non-AKI during Follow-Up, n=1724P Value
Characteristics at cohort entry
 Age at cohort entry, mean (±SD), yr63.3 (±12.4)63.9 (±11.6)63.2 (±12.5)0.35
 Women, N (%)900 (43.9%)145 (44.8%)755 (43.8%)0.75
 Black race, N (%)361 (17.6%)59 (18.2%)302 (17.5%)0.76
 eGFR at cohort entry, ml/min per 1.73 m2
  Median [interquartile range]62.9 [46.9–84.6]57.1 [43.8–81.0]63.9 [48.3–85.1]<0.01
 Urine protein-to-creatinine ratio at cohort entry (g/g)
  Median [interquartile range]0.12 [0.07–0.25]0.17 [0.09–0.42]0.11 [0.07–0.23]<0.001
 Diabetes mellitus, N (%)805 (39.3)186 (57.4)619 (35.9)<0.001
 Use of ACE-I or ARB at cohort entry, N (%)989 (48.3)175 (54.0)814 (47.2)<0.05
 No. of BP medications at cohort entry
  Median [interquartile range]2 [1–2]2 [1–3]2 [1–2]<0.001
 Systolic BP at cohort entry, mm Hg
  Mean (±SD)126 (±21)129 (±23)126 (±21)<0.05
 Diastolic BP at cohort entry, mm Hg
  Mean (±SD)71 (±14)71 (±14)71 (±13)0.87
Follow-up characteristics
 Follow-up time (year)
 Median [interquartile range]3.9 [2.0–5.8]4.0 [2.8–5.7]3.9 [1.9–5.8]0.12
  • ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.